An investigation of the toxicity of gadolinium based MRI contrast agents using neutron activation analysis

Magnetic Resonance Imaging

Volumn 21, Issue 5, 2003, Pages 541-544

  Bartolini, M E ^a   Pekar, J ^a   Chettle, D R ^a   McNeill, F ^a   Scott, A ^b   Sykes, J ^c   Prato, F S ^c   Moran, G R ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b HAMILTON HEALTH SCIENCES   (Canada)

^c LAWSON HEALTH RESEARCH INSTITUTE   (Canada)

Author keywords

Contrast agents; Gadolinium; Magnetic resonance imaging; Neutron activation analysis; Toxicity

Indexed keywords

GADOLINIUM; GADOLINIUM PENTETATE; GADOTERIDOL; NUCLEAR MAGNETIC RESONANCE IMAGING AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BOLUS INJECTION; CONTINUOUS INFUSION; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DOG; KIDNEY; LIVER; NEUTRON ACTIVATION ANALYSIS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; TOXICITY TESTING;

ANIMALIA;

EID: 0041306205     PISSN: 0730725X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0730-725X(03)00081-X     Document Type: Article

References (15)

1. Shellock FG, Kanal E. Safety of MRI contrast agents. JMRI 1999;10:477-84.
2. Wedeking P, Eaton S, Linder KE, Johnstone J, Tweedle MF. Tissue distribution of 153Gd-labeled gadoversetamide in mice. Pro Intl Soc Mag Reson Med 2001:9.
3. Carr DH, Brown J, Bydder GM, Steiner RE, Weinmann HJ, Speck U, Hall AS, Young IR. Gadolinium-DTPA as a contrast agent in MRI: initial clinical experience in 20 patients. Am J Roentgenol 1984;143(2):215-24.
4. Flacke SJ, Fischer SE, Lorenz CH. Measurement of the gadopentetate dimeglumine partition coefficient in human myocardium in vivo: normal distribution and elevation in acute and chronic infarction. Radiology 2001;218:703-10.
5. Moran GR, Thornhill RE, Sykes J, Prato FS. Myocardial viability imaging using Gd-DTPA: physiological modeling of infarcted myocardium and impact on injection strategy and imaging time. Magn Reson Med, Accepted with Revisions June 2002. June 2001.
6. Pereira RS, et al. Magnetic resonance materials in physics, biology and medicine. 2000;11:104-13.
7. Wedeking P, Eaton S, Tweedle MF, Eckleman WC. Multi-tissue pharmacokinetic evaluation of MRI contrast agents. 8th Annual Meeting, International Society of Magnetic Imaging in Medicine, Amsterdam, The Netherlands; 802; 1989.
8. Weinmann HJ, Press WR, Gries H. Tolerance of extracellular contrast agents for magnetic resonance imaging. Invest Radiol 1990;25:S49-50.
9. Boudreau RJ, Burbidge S, Stirr S, Loken MK. Comparison of the biodistribution of maganesium-54 DTPA and gadolinium-153 DTPA in dogs. J Nucl Med 1987;28:349-53.
10. Wedeking P, Kumar K, Tweedle MF. Dissociation of gadolinium chelates in mice: relationship to chemical characterisitics. Magn Reson Imag 1992;10:641-8.
11. Prato FS, Wisenberg G, Marshall TP, Uksik P, Zabel P. Comparison of the biodistribution of gadolinium- 153 DTPA and technetium-99m DTPA in rats. J Nucl Med Oct 1988;29(10):1683-7.
12. Yoneda S, Emi N, Fujita Y, Ohmichi M, Hirano S, Suzuki KT. Effects of gadolinium chloride on the rat following intratracheal instillation. Fundam Appl Toxicol Nov 1995;28(1):65-70.
13. Glascock MD. Principles of neutron activation analysis. Research Reactor Facility. Columbia: University of Missouri, 1988; 3.
14. DeBievre P, Taylor PDP. Int J Mass Spectrom Ion Phys 1993;123:149.
15. n in mice. Nucl Med Biol 1988;15:395-402.